Skip to main content
S&P 5007,799.58-0.25%DOW51,181.62-0.66%NASDAQ27,506.69-0.34%BTC$83,360.00-2.42%ETH$2,560.81-4.68%GOLD$4,133.20-1.29%OIL$88.91-0.59%
Smart Investors Daily
SID Premium
LE

NASDAQ · LEGN

Legend Biotech Corporation

Healthcare · Biotechnology

$18.72

Up+$0.37 (+1.98%)

Updated Oct 7, 2026, 7:15 PM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.12B
P/E ratio
-6.5
Dividend yield
0.00%
52-week range
$16.24 – $37.50
Volume
1.35M
Avg. volume
1.71M

Price performance · LEGN

LEGN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

LEGN closed at $18.72 after 21 trading sessions, down 8.64% for the selected period.

Last close
$18.72
Period change
-8.64%
Period low
$17.00
Period high
$20.49
Daily close
View OHLC price history
LEGN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$19.00$19.25$18.55$18.721.35M
Oct 5, 2026$18.495$18.82$17.9153$18.7751.76M
Oct 2, 2026$19.35$19.64$18.52$18.572.53M
Oct 1, 2026$19.61$19.78$19.19$19.322.22M
Sep 30, 2026$18.90$20.00$18.85$19.892.96M
Sep 29, 2026$18.50$19.26$18.46$18.821.97M
Sep 28, 2026$18.80$18.89$18.40$18.621.71M
Sep 25, 2026$19.49$19.69$18.85$19.111.43M
Sep 24, 2026$18.30$19.12$18.15$19.061.78M
Sep 23, 2026$18.62$19.08$18.275$18.452.41M
Sep 22, 2026$18.85$18.86$18.41$18.642.31M
Sep 21, 2026$17.952$18.645$17.81$18.532.83M
Sep 18, 2026$17.71$17.875$17.22$17.612.94M
Sep 17, 2026$17.38$17.8529$17.30$17.581.95M
Sep 16, 2026$17.86$18.04$16.86$17.003.53M
Sep 15, 2026$18.60$18.63$17.52$17.673.47M
Sep 14, 2026$18.80$18.80$18.21$18.533.25M
Sep 11, 2026$19.48$19.85$18.61$18.644.28M
Sep 10, 2026$19.70$19.88$19.15$19.191.82M
Sep 9, 2026$20.22$20.52$19.76$19.911.36M
Sep 8, 2026$21.625$21.97$20.43$20.491.59M

Latest LEGN news

The latest Smart Investors Daily articles mentioning LEGN.

Stock researchCompany · Overview

LEGN research

Overview

Company profile and research snapshot.

Company profile

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$60.67
Implied upside
—
Analysts
24
LEGN recent ratings
DateFirmRatingTarget
Sep 30, 2026HC Wainwright & Co.Buy—
Sep 11, 2026BarclaysOverweight—
Sep 4, 2026HC Wainwright & Co.Buy—
Aug 12, 2026OppenheimerPerform—
Aug 12, 2026TD CowenHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 4, 2026

Legend Biotech (LEGN) Tests Its Valuation After Fresh CARVYKTI Five Year Data

Legend Biotech (LEGN) moved back into focus after releasing five-year follow-up data from its CARTITUDE-2 Cohort A study of CARVYKTI in relapsed or refractory multiple myeloma patients. Despite the encouraging CARTITUDE-2 update, Legend Biotech’s recent trading tells a more cautious story. The share price is down about 3.9% over the past day and roughly 13.7% over 30 days, contributing to a 1-year total shareholder return decline of 42.1% and a 5-year total shareholder return decline of...

Yahoo · Oct 1, 2026

Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma

Annual program will award funding to early-career healthcare professionals advancing research, education, and innovation in multiple myeloma BRIDGEWATER, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the launch of its inaugural Emerging Leadership & Innovation in Cell Therapy Excellence (ELITE) Program, an annual grant initiative designed to recognize and support early-career healthcare profess

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By